Personalized Therapy in Non-Small Cell Lung Cancer: The Role of Biological Agents and Immunotherapy

Message from the Guest Editor

It is no longer acceptable to lump lung cancer into either small cell or non-small cell groups. With the advent of targeted therapy for cancers with mutations or rearrangements, and the increasing role for immunotherapy, there is an increasing need for precise pathology assessment and individualized therapy. This is an exciting time in lung cancer care, but these developments also require clinicians involved in lung cancer to be up to date with all new developments. Hopefully this Special Issue will assist clinicians in being aware of state-of-the-art lung cancer care.

Prof. David J. Barnes
Guest Editor